TY  - GEN 
AU  - Martinón Torres, Federico
AU  - Rusch, S.
AU  - Huntjens, D.
AU  - Remmerie, B.
AU  - Vingerhoets, J.
AU  - McFadyen, K.
AU  - Ferrero, F.
AU  - Baraldi, E.
AU  - Rojo, P.
AU  - Epalza, C.
AU  - Stevens, M.
PY  - 2020
SN  - 1058-4838
UR  - http://hdl.handle.net/20.500.11940/16537
AB  - BACKGROUND: This phase 1b study evaluated the pharmacokinetics, safety, and antiviral effects of the respiratory syncytial virus (RSV)-specific fusion inhibitor JNJ-53718678 (JNJ-8678) in hospitalized RSV-infected patients aged > 1 to </=24 months....
KW  - Humans
KW  - Indoles
KW  - Aged
KW  - Double-Blind Method
KW  - Antiviral Agents
KW  - Infant
TI  - Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study
DO  - 10.1093/cid/ciaa283
KW  - CHUS
VL  - 71
ER  -